QR-Code

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations

Abstract Background In patients with non‐small cell lung cancer (NSCLC) harboring driver alterations, the efficacy of immune checkpoint inhibitors (ICIs) remains uncertain. Our study aimed to examine the first‐line ICI efficacy in patients with NSCLC harboring KRAS, MET, FGFR, RET, BRAF, and HER2 al...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Yuji Uehara, Kageaki Watanabe, Taiki Hakozaki, Makiko Yomota, Yukio Hosomi
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2022-06-01
Schriftenreihe:Thoracic Cancer
Schlagworte:
immunotherapy
KRAS mutation
lung cancer
MET mutation
oncogenic drivers
Online-Zugang:https://doi.org/10.1111/1759-7714.14448
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge